Holen Sie sich die Stockscreener-App
0.712
0.76%
0.0054
Handel nachbörslich:
.70
-0.012
-1.69%
Schlusskurs vom Vortag:
$0.7066
Offen:
$0.665
24-Stunden-Volumen:
431.26K
Relative Volume:
0.29
Marktkapitalisierung:
$10.20M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-3.85M
KGV:
-1.0319
EPS:
-0.69
Netto-Cashflow:
$-1.94M
1W Leistung:
-17.84%
1M Leistung:
-90.31%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$0.66
$0.7399
1-Wochen-Bereich:
$0.66
$0.8181
52-Wochen-Spanne:
$0.66
$9.40
Lakewood Amedex Biotherapeutics Inc Stock (LABT) Company Profile
Firmenname
Lakewood Amedex Biotherapeutics Inc
Sektor
Branche
Telefon
(941) 225-2515
Adresse
8031 COOPER CREEK BLVD., UNIVERSITY PARK
Compare LABT vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LABT
Lakewood Amedex Biotherapeutics Inc
|
0.712 | 10.12M | 0 | -3.85M | -1.94M | -0.69 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lakewood Amedex Biotherapeutics Inc Aktie (LABT) Neueste Nachrichten
Lakewood-Amedex stock falls despite positive Nu-3 manufacturing update - MSN
Lakewood-Amedex Biotherapeutics Inc. Reports Q1 2026 Financial Results and Advances in Antimicrobial Therapy Development - Minichart
Lakewood-Amedex Biotherapeutics Inc. 1Q 2026: Revenue ($886.75K), EPS ($0.2) — 10-Q Summary - TradingView
LABT SEC FilingsLakewood-Amedex 10-K, 10-Q, 8-K Forms - Stock Titan
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
LABT News | LAKEWOOD-AMEDEX BIOTHERAPEUT (NASDAQ:LABT) - ChartMill
Lakewood-Amedex Biotherapeutics(LABT) Stock Options Chain | Quotes & News - Moomoo
Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) AI-Powered Stock Analysis - Meyka
Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers - Sahm
Lakewood-Amedex Stock Falls Despite Positive Nu-3 Manufacturing Update - Sahm
Lakewood-Amedex Biotherapeutics advances production of foot ulcer candidate Nu3 - TipRanks
Positive Nu-3 Data Advances Lakewood-Amedex Toward Phase 2 Diabetic Foot Ulcer Trial (LABT) - Yahoo Finance
Lakewood-Amedex completes manufacturing steps for Nu-3 trial By Investing.com - Investing.com South Africa
LABT Stock Slides As Volatility Grips Biotech Micro-Cap - StocksToTrade
Lakewood-Amedex Provides Progress Update Of Nu-3 In Diabetic Foot Ulcers; Stock Down - RTTNews
Lakewood-Amedex Biotherapeutics Announces Positive Data For The Advancement Of Lead Candidate, Nu-3 - TradingView
LABT Stock Slides As Volatility Tests Biotech Day Traders - timothysykes.com
Lakewood-Amedex completes manufacturing steps for Nu-3 trial - Investing.com
LABT Price Today: Lakewood-Amedex Biotherapeutics Inc. Stock Price, Quote & Chart | MEXC - MEXC
Lakewood-Amedex Biotherapeutics Inc (LABT) Stock Price, Quote, News & History - Benzinga
Lakewood-Amedex jumps 20% in Nasdaq market debut - MSN
LABT Should I Buy - Intellectia AI
Lakewood‑Amedex (LABT) registers 9.65M shares tied to Series C conversion - Stock Titan
[EFFECT] Lakewood-Amedex Biotherapeutics Inc. SEC Filing - Stock Titan
LABT Stock Price, Quote & Chart | LAKEWOOD-AMEDEX BIOTHERAPEUT (NASDAQ:LABT) - ChartMill
Lakewood-Amedex selects PERI as CRO for Nu-3 phase 2 trial - Investing.com UK
Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to - GuruFocus
Lakewood-Amedex selects PERI as CRO for Nu-3 phase 2 trial By Investing.com - Investing.com South Africa
Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3 - PR Newswire
Lakewood-Amedex (LABT) Stock Analysis Report | Financials & Insights - Benzinga
Lakewood-Amedex Biotherapeutics Inc. (LABT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) Competitors - Meyka
This newly listed biotech is soaring – retail says $14 is the line in the sand - MSN
Number of shareholders of Lakewood-Amedex Biotherapeutics Inc. – NASDAQ:LABT - TradingView
Lakewood-Amedex Biotherapeutics (LABT) director files Form 3 with zero shares - Stock Titan
Lakewood-Amedex reports promising AMR data for Nu-3 in iDFU - Clinical Trials Arena
Lakewood Amedex Advances Nu 3 Bisphosphocin Candidate With Strong AMR Resistance Profile - BioPharma APAC
Lakewood-Amedex (LABT) director lists stock and warrant holdings - Stock Titan
Lakewood-Amedex (LABT) Chief Medical Officer reports stock and option holdings - Stock Titan
LABT CEO Kelvin Cooper discloses 300,594 shares and options in Form 3 - Stock Titan
Lakewood-Amedex (LABT) CFO reports 468K shares and large option grants - Stock Titan
Lakewood-Amedex (LABT) S-1 resale tied to Series C funding and Nu-3 - Stock Titan
Biotech Stocks To Follow TodayMay 1st - MarketBeat
LABT Stock Volatility Draws Traders After Sharp Pullback - StocksToTrade
Lakewood-Amedex Biotherapeutics Announces Positive Antimicrobial Resistance Data For Lead Candidate Targeting Infected Diabetic Foot Ulcers - TradingView
LABT Stock Slides As Volatility Grips Thinly Capitalized Biotech - timothysykes.com
Lakewood-Amedex reports resistance data for diabetic ulcer drug By Investing.com - Investing.com South Africa
Lakewood-Amedex Biotherapeutics’ lead candidate in foot ulcers shows efficacy - TipRanks
$Lakewood-Amedex Biotherapeutics (LABT.US)$ Hopefully I'll have some sweet dreams tonight. - Moomoo
Lakewood-Amedex reports resistance data for diabetic ulcer drug - Investing.com
In 21-day lab tests, Nu-3 stayed active against resistant bacteria - Stock Titan
Finanzdaten der Lakewood Amedex Biotherapeutics Inc-Aktie (LABT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):